Agios Pharmaceuticals, Inc. (AGIO) is an innovative biopharmaceutical company established in 2008 that is advancing the field of cellular metabolism to treat cancer and rare genetic diseases. The American company is headquartered in Cambridge, Massachusetts, and is publicly traded and listed on the NASDAQ Stock Market.
The vision that drives Agios is to fundamentally change the way patients feel from devastating diseases by harnessing the power of cellular metabolism. The company's dedication to this vision has allowed it to express unique leadership in the field of cellular metabolism, enabling Agios to continually break boundaries with their research and therapeutics.
Agios has a robust pipeline of novel investigational medicines aimed at providing cutting-edge solutions for patients in areas where limited or no therapeutic options exist. Their focus on cancer involves developing therapies that have the ability to target and halt cancer cells' metabolic activities, thereby inhibiting their growth and proliferation. In the realm of rare genetic diseases, Agios is dedicated to understanding the root cause, as they occur due to mutations that affect the metabolism of certain cells.
Tibsovo® is one of Agios’ main products. It is the first and only FDA-approved therapy that targets the IDH1 mutation, commonly found in many types of cancer including Leukemia. In addition to Tibsovo®, Agios' portfolio includes a number of clinical-stage and investigational medicines such as Mitapivat for Pyruvate Kinase deficiency and Vorasidenib for IDH-mutant low-grade glioma, amongst others.
Agios' approach to medical discovery and development relies heavily on collaboration, which they engage in through partnerships with several other innovative companies and academic institutions. They conserve a multidisciplinary team of dedicated professionals who tackle the most complex health issues with scientific rigor and a spirit of innovation.
To fund its operations and research, Agios Pharmaceuticals, Inc. generates revenues mainly from product sales, collaboration agreements, and government funding. Throughout the years, Agios has faced challenges, but their commitment to research, innovation, and patient care has allowed them to remain at the forefront of their field. They continue to make strides in the biopharmaceutical sector through their ground-breaking research and development activities in the realm of cellular metabolism.
Ultimately, Agios Pharmaceuticals, Inc. is a pioneering company striving to translational medicine as they continue to push the boundaries in drug discovery and development, bringing new hope to patients through their novel, metabolism-based therapies. The journey of Agios Pharmaceuticals symbolizes the possible nexus between advancing science, commitment to patients, and commercial success.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Novo Nordisk has filed for approval of its oral pyruvate kinase-R (PKR) activator, etavopivat, for sickle cell disease (SCD) with both the FDA and EMA. This move positions Novo Nordisk in direct competition with Agios Pharmaceuticals, whose own candidate, mitapivat, recently experienced a delay in its FDA decision. The article highlights the intensifying race to market an oral PKR activator for SCD between the two pharmaceutical companies.
Agios Pharmaceuticals (AGIO) recently provided a third-quarter earnings update and news on its mitapivat regulatory review, showing a mixed performance with a 16.85% year-to-date gain but a 25.34% one-year decline. Analysts on Simply Wall St suggest the stock is 31% undervalued, with a fair value of $46.00 against a $31.76 close, primarily due to expectations for mitapivat's growth and pipeline assets. However, a high P/S ratio of 13.5x compared to an industry average of 10.3x indicates potential valuation risk if market sentiment shifts.
Agios Pharmaceuticals is reducing its research and development workforce by over 100 roles, representing more than a 35% cut. The Cambridge-based company is making this strategic shift to prioritize commercial launches and aims to achieve profitability by 2028. Agios is a commercial-stage company that develops medicines for patients with rare diseases.
Agios Pharmaceuticals reported record third-quarter product revenue of $55.4 million, a four-fold increase from the prior year, primarily driven by the U.S. launch of mitapivat in thalassemia. The company is preparing for the potential launch of mitapivat in sickle cell disease, with an FDA decision expected by February 2027, despite a recent request for additional safety data. Agios aims for non-GAAP profitability by 2028, supported by significant R&D headcount reductions and $907 million in cash reserves, while advancing its rare hematology pipeline.
AGIOS PHARMACEUTICALS ($AGIO) reported its Q3 2026 earnings, beating analyst estimates for both earnings per share and revenue. The company reported an EPS of -$1.09 against an estimated -$1.25, and revenue of $55.39 million against an estimated $54.27 million. The article also provides details on insider trading activity, hedge fund movements, congressional stock trading, and recent analyst price targets for AGIO.
Agios Pharmaceuticals announced that the FDA extended the PDUFA goal date for mitapivat's sickle cell disease sNDA to February 1, 2027, classifying updated safety information as a major amendment. This delay, while operational, highlights ongoing regulatory and commercial timing risks for investors. The company's investment narrative now focuses on its ability to address these requirements and build its commercial base.
The US FDA has extended its review deadline for Agios Pharmaceuticals' mitapivat, an oral pyruvate kinase activator for sickle cell disease, from November 1, 2026, to February 1, 2027. This three-month extension allows the agency to evaluate additional safety information submitted by Agios, classified as a major amendment, to determine if a Risk Evaluation and Mitigation Strategy (REMS) is required. Despite a boxed warning for liver injury with mitapivat in thalassemia, Agios asserts no similar severe liver injury has been reported in sickle cell patients, maintaining its positive benefit-risk assessment.